Astrazeneca Pharma India, 506820, ASTRAZEN Share Price, Rating, Research, Analysis, Fundamental & Historical Data

Stock Summary

Market Cap(Crs)
Stock P:E
Face Value

13,221.50
94.91
2

Enterprise Value(Crs)
Dividend Yield
Price:Book Value

12,701.25
0.30%
19.71

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

10 Years
5 Years
3 Years

7.78
6.61
7.23

EBITDA CAGR (%)

10 Years
5 Years
3 Years

-
18.29
4.04

PAT CAGR (%)

10 Years
5 Years
3 Years

-
12.77
2.10

P:E (Median)

8 Years
5 Years
3 Years

106.67
97.02
95.54

P:BV (Average)

8 Years
5 Years
3 Years

18.51
18.51
16.68

EV:EBITDA (Average)

8 Years
5 Years
3 Years

59.87
58.38
56.91

Quarterly Results

Standalone Figures in Rs. Crores /

Consolidated

Description Dec 23 Dec 22 Var% Sep 23 Sep 22 Var% Jun 23 Jun 22 Var% Mar 23 Mar 22 Var%
Net Sales 305.79 249.81 22.41% 311.07 236.13 31.74% 295.47 232.33 27.18% 284.70 231.96 22.74%
Expenses 290.73 213.22 36.35% 258.31 195.40 32.20% 228.22 204.37 11.67% 224.86 194.00 15.91%
EBITDA 15.06 36.59 -58.84% 52.76 40.73 29.54% 67.25 27.96 140.52% 59.85 37.96 57.67%
EBIDTM 4.92% 14.65% 16.96% 17.25% 22.76% 12.04% 21.02% 16.37%
Other Income 9.66 7.20 34.17% 8.37 6.79 23.27% 8.10 4.11 97.08% 8.00 3.68 117.39%
Interest 0.61 0.20 205.00% 0.50 0.16 212.50% 0.15 0.19 -21.05% 0.09 0.21 -57.14%
Depreciation 3.70 4.13 -10.41% 3.67 3.29 11.55% 3.80 4.59 -17.21% 4.25 4.41 -3.63%
PBT 20.40 39.46 -48.30% 73.38 44.07 66.51% 71.40 27.30 161.54% 23.28 37.03 -37.13%
Tax 4.60 10.15 -54.68% 21.02 11.50 82.78% 17.54 7.15 145.31% 6.01 9.05 -33.59%
PAT 15.80 29.31 -46.09% 52.37 32.56 60.84% 53.86 20.16 167.16% 17.27 27.98 -38.28%
PATM 5.17% 11.73% 16.84% 13.79% 18.23% 8.68% 6.07% 12.06%
EPS 6.32 11.72 -46.08% 20.95 13.03 60.78% 21.54 8.06 167.25% 6.91 11.19 -38.25%

Description Dec 23 Dec 22 Var% Sep 23 Sep 22 Var% Jun 23 Jun 22 Var% Mar 23 Mar 22 Var%
Net Sales 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
Expenses 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
EBITDA 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
EBIDTM 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Other Income 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
Interest 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
Depreciation 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
PBT 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
Tax 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
PAT 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
PATM 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EPS 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0

Annual Results

Standalone Figures in Rs. Crores

Description TTM Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14
Net Sales 1,197.03 1,002.97 805.60 813.56 831.81 728.29 571.00 543.71 563.73 517.07 473.97 Net Sales Growth 25.97% 24.50% -0.98% -2.19% 14.21% 27.55% 5.02% -3.55% 9.02% 9.09% Cost Of Goods Sold 479.44 355.22 305.28 287.30 299.97 226.73 178.21 171.18 194.81 194.23 155.08 Gross Profit 717.59 647.75 500.32 526.26 531.84 501.56 392.79 372.53 368.93 322.84 318.90 GP Margin 59.95% 64.58% 62.11% 64.69% 63.94% 68.87% 68.79% 68.52% 65.44% 62.44% 67.28% Total Expenditure 1,002.12 837.85 719.42 678.09 711.11 656.99 524.71 506.77 547.31 528.48 486.94 Power & Fuel Cost - 5.54 8.10 7.37 7.72 8.27 8.30 7.68 7.43 8.51 8.69 % Of Sales - 0.55% 1.01% 0.91% 0.93% 1.14% 1.45% 1.41% 1.32% 1.65% 1.83% Employee Cost - 259.10 230.21 219.54 216.70 197.40 150.39 162.04 169.35 159.84 160.46 % Of Sales - 25.83% 28.58% 26.99% 26.05% 27.10% 26.34% 29.80% 30.04% 30.91% 33.85% Manufacturing Exp. - 76.04 57.12 49.32 40.81 49.58 50.67 36.40 25.82 17.69 35.93 % Of Sales - 7.58% 7.09% 6.06% 4.91% 6.81% 8.87% 6.69% 4.58% 3.42% 7.58% General & Admin Exp. - 56.66 40.04 40.69 65.54 74.09 46.49 55.04 59.10 63.77 66.68 % Of Sales - 5.65% 4.97% 5.00% 7.88% 10.17% 8.14% 10.12% 10.48% 12.33% 14.07% Selling & Distn. Exp. - 71.57 62.09 55.94 65.13 88.18 81.07 62.56 84.65 77.77 55.54 % Of Sales - 7.14% 7.71% 6.88% 7.83% 12.11% 14.20% 11.51% 15.02% 15.04% 11.72% Miscellaneous Exp. - 13.72 16.58 17.93 15.24 12.74 9.58 11.87 6.16 6.67 55.54 % Of Sales - 1.37% 2.06% 2.20% 1.83% 1.75% 1.68% 2.18% 1.09% 1.29% 0.97% EBITDA 194.92 165.12 86.18 135.47 120.70 71.30 46.29 36.94 16.42 -11.41 -12.97 EBITDA Margin 16.28% 16.46% 10.70% 16.65% 14.51% 9.79% 8.11% 6.79% 2.91% -2.21% -2.74% Other Income 34.13 26.10 14.76 12.84 12.99 16.29 12.25 14.39 6.77 5.85 9.21 Interest 1.35 0.63 0.95 1.09 1.14 0.00 0.00 0.00 0.00 0.00 0.00 Depreciation 15.42 16.26 16.95 20.13 18.58 14.92 14.74 15.83 17.43 15.28 10.12 PBT 188.46 174.33 83.04 127.09 113.97 72.67 43.80 35.50 5.76 -20.84 -13.89 Tax 49.17 34.81 21.44 33.79 41.76 18.22 17.89 15.45 0.50 0.00 0.51 Tax Rate 26.09% 25.96% 25.82% 26.59% 36.64% 25.07% 40.84% 43.52% 8.68% 0.00% 0.00% PAT 139.30 99.29 61.60 93.30 72.21 54.45 25.91 20.05 5.26 -20.84 -0.51 PAT before Minority Interest 139.30 99.29 61.60 93.30 72.21 54.45 25.91 20.05 5.26 -20.84 -0.51 Minority Interest 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT Margin 11.64% 9.90% 7.65% 11.47% 8.68% 7.48% 4.54% 3.69% 0.93% -4.03% -0.11% PAT Growth 26.62% 61.19% -33.98% 29.21% 32.62% 110.15% 29.23% 281.18% - - EPS 55.72 39.72 24.64 37.32 28.88 21.78 10.36 8.02 2.10 -8.34 -0.20

Results Balance Sheet

Standalone Figures in Rs. Crores

Description Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14
Shareholder's Funds 588.69 511.39 456.17 364.44 300.80 246.93 222.87 156.01 150.76 171.60 Share Capital 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 Total Reserves 581.12 504.44 449.58 357.85 293.70 239.85 216.22 151.01 145.76 166.60 Non-Current Liabilities 68.99 73.63 44.60 44.13 22.75 109.73 88.68 38.96 1.02 0.49 Secured Loans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Unsecured Loans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Long Term Provisions 85.97 84.91 50.50 49.47 46.11 142.28 128.90 37.70 0.00 0.00 Current Liabilities 484.40 392.30 373.43 367.10 267.60 218.67 202.05 234.05 259.82 243.50 Trade Payables 227.88 190.44 178.37 209.72 168.20 127.20 87.66 94.63 111.27 109.87 Other Current Liabilities 111.95 94.23 82.58 71.06 54.38 39.41 69.84 121.08 111.60 96.50 Short Term Borrowings 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Short Term Provisions 144.57 107.63 112.48 86.32 45.02 52.06 44.55 18.33 36.95 37.13 Total Liabilities 1,142.08 977.32 874.20 775.67 591.15 575.33 513.60 429.02 411.60 415.59 Net Block 68.86 74.49 80.96 71.53 74.83 75.46 86.84 97.36 100.99 94.22 Gross Block 179.12 168.83 159.78 132.84 119.83 105.85 102.57 203.76 191.44 169.75 Accumulated Depreciation 110.26 94.34 78.82 61.31 45.00 30.39 15.73 106.40 90.46 75.53 Non Current Assets 206.14 212.00 185.51 193.49 177.81 242.69 250.34 161.95 148.33 140.96 Capital Work in Progress 1.33 2.20 4.02 24.24 6.90 3.57 4.81 6.31 12.21 9.31 Non Current Investment 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Long Term Loans & Adv. 135.95 135.31 100.52 97.71 95.83 163.39 158.27 57.68 34.55 37.06 Other Non Current Assets 0.00 0.00 0.01 0.01 0.25 0.27 0.42 0.61 0.59 0.37 Current Assets 935.94 765.32 688.69 582.18 413.34 332.64 263.26 267.07 263.26 274.62 Current Investments 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Inventories 190.21 140.22 159.80 165.15 118.10 113.15 57.71 76.73 86.13 95.76 Sundry Debtors 107.52 85.89 85.19 83.21 79.75 54.63 43.00 83.14 42.77 52.93 Cash & Bank 500.48 448.46 352.35 252.52 173.30 125.92 115.58 76.83 25.08 89.07 Other Current Assets 137.73 12.64 14.05 19.85 42.19 38.94 46.97 30.37 109.27 36.87 Short Term Loans & Adv. 124.17 78.11 77.30 61.45 29.25 30.87 23.43 20.22 107.46 32.33 Net Current Assets 451.54 373.02 315.26 215.08 145.74 113.97 61.21 33.03 3.44 31.12 Total Assets 1,142.08 977.32 874.20 775.67 591.15 575.33 513.60 429.02 411.59 415.58

Cash Flow

Standalone Figures in Rs. Crores

Description Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14
Cash From Operating Activity 58.29 100.80 104.78 87.42 54.98 8.79 38.10 56.99 -45.70 -0.81 PBT 134.10 83.04 127.09 113.97 72.67 43.80 35.50 5.76 -20.84 0.00 Adjustment -4.80 9.66 14.20 9.75 7.62 3.39 14.61 12.11 8.58 -10.85 Changes in Working Capital -30.19 32.89 -3.95 -2.66 9.81 -34.25 -0.24 42.09 -32.58 17.66 Cash after chg. in Working capital 99.11 125.59 137.34 121.06 90.10 12.94 49.87 59.97 -44.83 6.81 Interest Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Tax Paid -40.82 -24.79 -32.56 -33.64 -35.12 -4.15 -11.77 -2.98 -0.87 -7.62 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cash From Investing Activity 18.11 4.74 173.03 -170.80 4.28 -9.36 0.25 -3.61 -18.64 -14.57 Net Fixed Assets -9.42 -7.23 -6.72 -30.35 -17.31 -2.04 102.69 -6.42 -24.59 -6.72 Net Investments 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 Others 27.53 11.97 179.75 -140.45 21.59 -7.32 -102.44 2.81 5.95 -7.86 Cash from Financing Activity -24.48 -9.46 -8.97 -6.36 0.00 0.00 0.00 -0.51 0.00 86.22 Net Cash Inflow / Outflow 51.92 96.08 268.84 -89.74 59.26 -0.57 38.35 52.87 -64.34 70.84 Opening Cash & Equivalents 448.42 352.34 83.50 173.24 113.98 114.55 76.20 23.33 87.68 16.83 Closing Cash & Equivalent 500.34 448.42 352.34 83.50 173.24 113.98 114.55 76.20 23.33 87.68

Financial Ratios

Standalone

Description Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14
Book Value (Rs.) 234.45 203.78 181.83 145.14 119.48 97.94 88.49 62.41 60.30 68.64 ROA 9.37% 6.65% 11.31% 10.57% 9.34% 4.76% 4.25% 1.25% -5.04% -0.14% ROE 18.13% 12.78% 22.83% 21.83% 20.03% 11.12% 10.63% 3.43% -12.93% -0.38% ROCE 24.49% 17.36% 31.24% 34.61% 26.53% 18.65% 18.74% 3.76% -12.93% 0.00% Fixed Asset Turnover 5.79 4.93 5.58 6.58 6.45 5.49 3.58 2.88 2.91 3.61 Receivable days 35.03 38.57 37.62 35.75 33.67 31.15 41.96 40.32 33.27 30.50 Inventory Days 59.85 67.64 72.59 62.15 57.95 54.51 44.72 52.15 63.23 68.29 Payable days 214.92 220.48 246.52 99.66 91.40 73.21 75.53 75.14 85.66 81.76 Cash Conversion Cycle -120.04 -114.26 -136.32 -1.76 0.22 12.45 11.15 17.33 10.84 17.03 Total Debt/Equity 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Interest Cover 213.86 88.41 117.60 100.97 0.00 0.00 0.00 0.00 0.00 0.00

Top Investors:

nippon life india trustee ltd - various schemes

tejas bhalchandra trivedi

shivani tejas trivedi

minaxi bhalchandra trivedi

investor education and protection fund (iepf)

Annual Reports:

News Update:

AstraZeneca Pharma gets nod to import for sale, distribution of Trastuzumab deruxtecan lyophilized powder
27th Mar 2024, 12:00 PM

The company has received permission from the Central Drugs Standard Control Organisation
Read More
AstraZeneca Pharma India, Mankind Pharma enter into agreement
11th Mar 2024, 17:15 PM

AstraZeneca will retain the intellectual property rights to budesonide and formoterol fumarate dihydrate and will continue to be the Marketing Authorisation Holder and import license
Read More
Astrazeneca Pharma I - Quarterly Results
8th Feb 2024, 18:17 PM

Read More
AstraZeneca Pharma gets nod to import pharmaceutical formulations of new drug for sale
20th Jan 2024, 16:59 PM

The company has received permission from Central Drugs Standard Control Organisation
Read More

Astrazeneca Pharma India Ltd.

Pharmaceuticals & Drugs - Domestic

BSE: 506820 | NSE: ASTRAZEN

Stock Summary

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Quarterly Results

Standalone Figures in Rs. Crores /

Annual Results

Standalone Figures in Rs. Crores

Results Balance Sheet

Standalone Figures in Rs. Crores

Cash Flow

Standalone Figures in Rs. Crores

Financial Ratios

Standalone

Top Investors:

Annual Reports:

News Update:

Astrazeneca Pharma India Ltd.

Pharmaceuticals & Drugs - Domestic

BSE: 506820 | NSE: ASTRAZEN

Stock Summary

Shareholding Pattern

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Quarterly Results

Standalone Figures in Rs. Crores /

Annual Results

Standalone Figures in Rs. Crores

Results Balance Sheet

Standalone Figures in Rs. Crores

Cash Flow

Standalone Figures in Rs. Crores

Financial Ratios

Standalone

Top Investors:

Annual Reports:

News Update: